HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bortolotti, U. Articles by Gallucci, V. Search for Related Content PubMed PubMed Citation Articles by Bortolotti, U. Articles by Gallucci, V.

The Annals of Thoracic Surgery, Vol 51, 430-437, Copyright © 1991 by The Society of Thoracic Surgeons

ARTICLES

Failure of Hancock pericardial xenografts: is prophylactic bioprosthetic replacement justified?

U Bortolotti, A Milano, F Guerra, A Mazzucco, E Mossuto, G Thiene and V Gallucci
Department of Cardiovascular Surgery, University of Padova Medical School, Italy.

The incidence of major valve-related complications was evaluated in a series of patients in whom the Hancock pericardial xenograft was used for aortic (AVR; n = 84), mitral (MVR; n = 17) and mitral-aortic (MAVR; n = 13) valve replacement. At 7 years actuarial survival is 66% +/- 8% after AVR, 64% +/- 13% after MVR, and 41% +/- 15% after MAVR, whereas actuarial freedom from valve-related death is 79% +/- 7% after AVR, 78% +/- 13% after MVR, and 81% +/- 12% after MAVR. Actuarial freedom from thromboemboli and anticoagulant-related hemorrhage at 7 years is 93% +/- 4% and 98% +/- 2% after AVR and 83% +/- 10% and 88% +/- 11% after MVR; no such complications occurred after MAVR. Structural valve deterioration determined at reoperation, at autopsy, or by clinical investigation was observed in 34 patients with AVR (10.0 +/- 0.2%/patient-year), in 10 with MVR (10.6 +/- 3.3%/patient-year), and in 9 with MAVR (16.6 +/- 5.5%/patient-year). After AVR, 19 patients underwent reoperation and 2 died before reoperation; 4 patients with MVR underwent reoperation, and 7 patients with MAVR underwent reoperation and 1 died before reoperation. Seventy-eight percent of the current survivors (13 patients with AVR, 7 with MVR, and 1 with MAVR) have clinical evidence of valve failure. At 7 years actuarial freedom from structural deterioration of the Hancock pericardial xenograft is 25% +/- 7% after AVR, 29% +/- 14% after MVR, and 0% after MAVR.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				U. Bortolotti, G. Scioti, A. Milano, M. De Carlo, R. Codecasa, C. Nardi, and G. Tartarini Performance of 21-mm size perimount aortic bioprosthesis in the elderly Ann. Thorac. Surg., January 1, 2000; 69(1): 47 - 50. [Abstract] [Full Text] [PDF]

				M. R. Aupart, P. H. Neville, S. Hammami, A. L. Sirinelli, Y. A. Meurisse, and M. A. Marchand CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP J. Thorac. Cardiovasc. Surg., March 1, 1997; 113(3): 492 - 498. [Abstract] [Full Text]

				M. R. Aupart, A. L. Sirinelli, F. F. Diemont, Y. A. Meurisse, X. B. Dreyfus, and M. A. Marchand The Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients Ann. Thorac. Surg., February 1, 1996; 61(2): 615 - 620. [Abstract] [Full Text]